Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Shareholder Meeting (December 2024)
36 slides from Coloplast A/s Class B's shareholder meeting presentation, December 2024
Slide 1: Coloplast Annual General Meeting 2023/24
Coloplast Annual General Meeting 2023/24 Mike | user of ostomy products
Slide 2: Chairman of the Board
Chairman of the Board Lars Rasmussen 2
Slide 3: Board of Directors – Other shareholder-elected Board members
Board of Directors Other shareholder-elected Board members Annette Brüls Carsten Hellmann Jette Nygaard-Andersen Marianne Wiinholt 3
Slide 4: Board of Directors – Employee-elected Board members
Board of Directors Employee-elected Board members Thomas Barfod Roland Vendelbo Pedersen Nikolaj Kyhe Gundersen 4
Slide 5: Executive Leadership Team
Executive Leadership Team Kristian Villumsen Dorthe Rønnau President & CEO Executive Vice President, People & Culture Anders Lonning-Skovgaard Nicolai Buhl Andersen Executive Vice President Executive Vice President, & CFO Chronic Care Caroline Vagner Rosenstand Tommy Johns Jr Executive Vice Presiden
Slide 6: Coloplast Annual General Meeting 2023/24
Coloplast Annual General Meeting 2023/24 Torben | cathether user
Slide 7: Agenda
Agenda 1. Report by the Board of Directors 2. Presentation and approval of the Annual Report 3. Resolution on the distribution of profit 4. Presentation and approval of the Remuneration Report 5. Approval of the remuneration of the Board of Directors 6. Proposals from the Board of Directors 7. Elect
Slide 8: Agenda
Agenda 1. Report by the Board of Directors 2. Presentation and approval of the Annual Report 3. Resolution on the distribution of profit 4. Presentation and approval of the Remuneration Report 5. Approval of the remuneration of the Board of Directors 6. Proposals from the Board of Directors 7. Elect
Slide 9: Chairman of the Board
Chairman of the Board Lars Rasmussen 9
Slide 10: Solid annual result
NEW IMAGE Solidt annual result 8% 27%* Organic growth EBIT margin *before special items 10 Rosemary | uses ostomy products
Slide 11: This year, Coloplast helped more than 2,000,000 people
This year, Coloplast helped more than 2,000,000 people with intimate healthcare needs Jason | catheter user 11
Slide 12: Executive Leadership Team
Executive Leadership Team Kristian Villumsen Dorthe Rønnau President & CEO Executive Vice President, People & Culture Anders Lonning-Skovgaard Nicolai Buhl Andersen Executive Vice President Executive Vice President, & CFO Chronic Care Caroline Vagner Rosenstand Tommy Johns Jr Executive Vice Presiden
Slide 13: Strive25 – focus on innovation and growth
Strive25 – focus on innovation and growth Continence Care Ostomy Care Voice & Respiratory Care Interventional Advanced Wound Care Urology Innovation Leadership, culture & organisation Unparallelled Sustainability efficiency 13 Yunguang | wound patient
Slide 14: Growth platform #1 Chronic Care
Growth platform #1 Chronic Care v Our Ostomy care market mission 23-24 bn DKK 4-5% Global market size Market growth annually 35-40% #1 Market share globally Market position globally v Our Continence mission care market 18-19 bn DKK 5-6% Global market size Market growth annually 40-45% #1 Market shar
Slide 15: Growth platform #2 Voice & Respiratory Care
Growth platform #2 Voice & Respiratory Care v Our Market for laryngectomy mission 1.5-2.0 bn DKK 8-10% Global market size Market growth annually ~85% #1 Market share globally Market position globally Giorgio | uses Atos Medical products
Slide 16: Growth platform #3 Advanced Wound Care
Growth platform #3 Advanced Wound Care v Our Advanced wound care mission Wound dressings / Biologics market* 44-48 bn DKK 2-4% / 6-8% Globl market size Market growth annually 5-10% #5 Market share globally Market position globally *Market size for Advanced dressings and Biologics Abdallah | wound pa
Slide 17: Growth platform #4 Interventional Urology
Growth platform #4 Interventional Urology v Our Urology market mission 18-20 bn DKK 4-6% Market size globally Market growth annually ~15% #4 Global market share Market position globally Colin | has a penile implant
Slide 18: Strive25 – Unparallelled efficiency
Strive25 – Unparallelled efficiency Continence Care Ostomy Care Voice & Respiratory Care Interventional Advanced Wound Care Urology Innovation Leadership, culture & organisation Unparallelled Sustainability efficiency 18 Yunguang | wound patient
Slide 19: Strive25 – Sustainability
Strive25 – Sustainability Continence Care Ostomy Care Voice & Respiratory Care Interventional Advanced Wound Care Urology Innovation Leadership, culture & organisation Unparallelled Sustainability efficiency 19
Slide 20: Strive25 – Leadership, culture & organisation
Strive25 – Leadership, culture & organisation Continence Care Ostomy Care Voice & Respiratory Care Interventional Advanced Wound Care Urology Innovation Leadership, culture & organisation Unparallelled Sustainability efficiency 20 Employees
Slide 21: Key ratios 2023/24
Key ratios 2023/24 mDKK 2023/24 2022/23 Change Net revenue 27,030 24,500 10% Gross margin 68% 67% 1% pp Operating profit (EBIT) 7,286* 6,845* 6% Operating margin (EBIT margin) 27%* 28%* -1 pp ROIC after tax 15%* 17%* -2% pp *Before special items 21
Slide 22: Profit 2023/24
Profit 2023/24 Net profit for the year DKK 5,052m Total assets DKK 48,073m Equity DKK 17,942m Free cash flow for the year DKK 1,430m Net interest-bearing debt* DKK 21,841m Dividend DKK 22.00 per DKK 4,956m share Pay-out ratio 98% * Includes an extraordinary tax payment of DKK 2.5 billion due to the
Slide 23: Share price development
Share price development 1,100 1,050 887 DKK 1,000 4 December 2024 950 748 DKK 900 29 September 2023 850 800 750 700 650 600 1.10.23 1.11.23 1.12.23 1.1.24 1.2.24 1.3.24 1.4.24 1.5.24 1.6.24 1.7.24 1.8.24 1.9.24 1.10.24 1.11.24 1.12.24 23 Coloplast’s share price development in DKK
Slide 24: Outlook and guidance for 2024/25
Outlook and guidance for 2024/25 8-9% ~28% * Reported Organic growth EBIT margin 24 *Before special items
Slide 25: [Show Pete Reed film]
[Show Pete Reed film] © colopiast
Slide 26: Coloplast Annual General Meeting 2023/24
Coloplast Annual General Meeting 2023/24 Torben | cathether user
Slide 27: Agenda
Agenda 1. Report by the Board of Directors 2. Presentation and approval of the Annual Report 3. Resolution on the distribution of profit 4. Presentation and approval of the Remuneration Report 5. Approval of the remuneration of the Board of Directors 6. Proposals from the Board of Directors 7. Elect
Slide 28: Agenda
Agenda 1. Report by the Board of Directors 2. Presentation and approval of the Annual Report 3. Resolution on the distribution of profit 4. Presentation and approval of the Remuneration Report 5. Approval of the remuneration of the Board of Directors 6. Proposals from the Board of Directors 7. Elect
Slide 29: 5. Approval of the remuneration of the Board of Directors
5. Approval of the remuneration of the Board of Directors The Board of Directors proposes that the remuneration for the Board of Directors for the financial year 2024/25 be set as follows: • Ordinary members of the Board are to receive a base fee of DKK 500,000. • The Vice Chair is to receive a fee
Slide 30: Agenda
Agenda 1. Report by the Board of Directors 2. Presentation and approval of the Annual Report 3. Resolution on the distribution of profit 4. Presentation and approval of the Remuneration Report 5. Approval of the remuneration of the Board of Directors 6. Proposals from the Board of Directors 7. Elect
Slide 31: Agenda
Agenda 1. Report by the Board of Directors 2. Presentation and approval of the Annual Report 3. Resolution on the distribution of profit 4. Presentation and approval of the Remuneration Report 5. Approval of the remuneration of the Board of Directors 6. Proposals from the Board of Directors 7. Elect
Slide 32: 7. Election of members to the Board of Directors
7. Election of members to the Board of Directors The following members of the Board of Directors are proposed for re- election: • Lars Rasmussen • Niels Peter Louis-Hansen • Annette Brüls • Carsten Hellmann • Jette Nygaard-Andersen • Marianne Wiinholt 32
Slide 33: Agenda
Agenda 1. Report by the Board of Directors 2. Presentation and approval of the Annual Report 3. Resolution on the distribution of profit 4. Presentation and approval of the Remuneration Report 5. Approval of the remuneration of the Board of Directors 6. Proposals from the Board of Directors 7. Elect
Slide 34: Agenda
Agenda 1. Report by the Board of Directors 2. Presentation and approval of the Annual Report 3. Resolution on the distribution of profit 4. Presentation and approval of the Remuneration Report 5. Approval of the remuneration of the Board of Directors 6. Proposals from the Board of Directors 7. Elect
Slide 35: Agenda
Agenda 1. Report by the Board of Directors 2. Presentation and approval of the Annual Report 3. Resolution on the distribution of profit 4. Presentation and approval of the Remuneration Report 5. Approval of the remuneration of the Board of Directors 6. Proposals from the Board of Directors 7. Elect
Slide 36: Coloplast
= Coloplast